The Pharmacometabolomics Research Network for Drug Response Phenotype was established with funding from NIGMS with the goal of integrating the rapidly evolving science of metabolomics with molecular pharmacology and pharmacogenomics to move toward the creation of a new discipline – “Pharmacometabolomics”. The formed multi-institutional Consortium involves centers of excellence in metabolomics and metabolomic bioinformatics, together with centers of excellence for molecular pharmacologic and pharmacogenomic science. That union would have the potential to accelerate advances in our understanding of mechanisms of drug action and individual variation in the drug response phenotypes. Additionally it would provide insights into disease mechanisms and heterogeneity within a disease state. The network brings an integration of metabolomics data with genomic data, transcriptomic data, drug level and drug metabolite data as well as clinical data – making it possible for the first time to take a true systems approach to the study of drug therapy and a true “Systems Pharmacology” approach. Key classes of drugs being studied in partnerships with members of the Pharmacogenetics Research Network include prototypic agents for the treatment of cardiovascular disease and neuropsychiatric diseases.
Components of the Pharmacometabolomics Research Network